Teva Pharm Q2 profit beats estimates as branded drugs gain

JERUSALEM, July 30 (Reuters) - Teva Pharmaceutical Industries TEVA.TA reported a higher than expected rise in second-quarter profit, helped by strong sales gains of its branded drugs to treat migraines, Huntington's disease and schizophrenia.

The world's largest generic drugmaker TEVA.N said on Wednesday it earned 66 cents per diluted share, excluding one-time items, in the April-June quarter, up from 61 cents a share a year earlier. Revenue was flat in dollar terms at $4.18 billion.

Analysts had forecast earnings of 62 cents per share ex-items for the Israel-based company on revenue of $4.28 billion, LSEG I/B/E/S data showed.

Teva largely reaffirmed its 2025 estimates but revised its adjusted EPS forecast to $2.50-$2.65 from $2.45-$2.65.